Paul Moore
Direttore Tecnico/Scientifico/R&S presso ZYMEWORKS INC.
Patrimonio netto: 62 472 $ in data 31/05/2024
Profilo
Paul A.
Moore is currently the Chief Scientific Officer at Zymeworks BC, Inc. and Zymeworks, Inc. He previously worked as the Vice President of Cell Biology & Immunology at MacroGenics, Inc. and as the Director of Cell Biology at Celera Corp.
He also worked as the Director of Lead Product Development at Human Genome Sciences, Inc. Moore holds a doctorate degree from the University of Glasgow and an undergraduate degree from the University of Strathclyde.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ZYMEWORKS INC.
0.01% | 08/01/2024 | 7 367 ( 0.01% ) | 62 472 $ | 31/05/2024 |
Posizioni attive di Paul Moore
| Società | Posizione | Inizio |
|---|---|---|
| ZYMEWORKS INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2022 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Direttore Tecnico/Scientifico/R&S | 18/07/2022 |
Precedenti posizioni note di Paul Moore
| Società | Posizione | Fine |
|---|---|---|
| MACROGENICS, INC. | Corporate Officer/Principal | 01/07/2022 |
Celera Corp.
 Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01/04/2008 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Formazione di Paul Moore
| University of Strathclyde | Undergraduate Degree |
| University of Glasgow | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Celera Corp.
Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Health Services |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Paul Moore
